A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies (CheckMate 370: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 370)
||Male and Female Patients
|U.S. Govt. ID:
||Catherine Shu: 212-305-3997 / firstname.lastname@example.org
The purpose of this master study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558) alone or in combination with standard of care therapies.
This study is closed
Catherine Shu, MD
|Have you been diagnosed with Non-Small-Cell Lung Cancer?